Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: A Pilot Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Lingling Jia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Alopecia Areata, Betamethasone, Glucocorticoids, Intercellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The East hospital affiliated to Tongji University introduced talent research startup fund, The Featured Clinical Discipline Project of Shanghai Pudong fund.
Abstract (Originalsprache)
Background
Alopecia areata (AA), an autoimmune disorder characterized by hair loss, can be particularly difficult to manage when patients do not respond to standard therapeutic approaches such as topical or injectable corticosteroids, contact immunotherapy, and systemic treatments. In instances where these conventional therapies prove ineffective, alternative or adjunctive treatments are sought. Concentrated growth factor (CGF) and microneedling (MN)‐assisted drug delivery are promising methods for the treatment of different dermatological diseases.
Objective
This study aimed to assess the practical benefits and the safety aspects of utilizing a dual treatment approach involving CGF and MN‐assisted compound betamethasone for patients suffering from resistant AA that are unresponsive to conventional medical interventions. Material and Methods This retrospective study was based on evaluations of seven patients with refractory AA treated with CGF and MN‐assisted compound betamethasone from July 2021 to December 2023. The efficacy of treatment was assessed by extents of hair regrowth percentages of involved areas.
Results
Among the seven enrolled patients with refractory AA, a notable outcome was observed where one patient (14.3%) achieved a regrowth of hair by over 50%, while six patients (85.7%) exhibited complete recovery without any systemic or local adverse effects. Furthermore, the difference in SALT scores between baseline, and the final visit for all patients was found to be statistically significant, substantiating the therapeutic efficacy of the intervention employed.
Conclusion
The present study demonstrated that the synergistic application of CGF in conjunction with MN‐assisted compound betamethasone may constitute a promising and well‐tolerated therapeutic modality for refractory AA, offering a potentially efficacious and safe treatment alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
ORCID-Profile: Jiachao Xiong
Förderung
- The East hospital affiliated to Tongji University introduced talent research startup fund
- The Featured Clinical Discipline Project of Shanghai Pudong fund
Zitieren
APA
Jia, L., Zhao, C., Zhang, H., Jiang, H., Xiong, J., & Li, Y. (2025). Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: A Pilot Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16591
Vancouver
Jia L, Zhao C, Zhang H, Jiang H, Xiong J, Li Y. Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: A Pilot Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16591
BibTeX
@article{Jia2025,
author = {Jia, Lingling and Zhao, Changjiang and Zhang, Hongyi and Jiang, Hua and Xiong, Jiachao and Li, Yufei},
title = {Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: A Pilot Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16591}
}
EUVIMED